Shri G.H. Patel Pharmacy Building, Centre for Postgraduate Studies in Pharmacy, TIFAC Core in NDDS, Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Fatehgunj, Vadodara 390002, India.
Institute of Nuclear Medicine and Allied Sciences, Brig. S.K. Mazumdar Marg, Delhi, India.
Pulm Pharmacol Ther. 2018 Apr;49:36-45. doi: 10.1016/j.pupt.2018.01.002. Epub 2018 Jan 12.
Vinorelbine Tartrate (VLB) is the first line chemotherapeutic agent for treatment of Non-Small Cell Lung Cancer, whose non-specific distribution causes unwanted side effects. The aim of the present investigation was to formulate VLB loaded spherulites intended for targeting the lung. Spherulites were composed of Soyabean Phosphatidylcholine (SPC), Cholesterol (Chol), Potassium oleate and Mannitol. Lipid film prepared using SPC, Chol and Potassium oleate, was dispersed in aqueous phase comprising Mannitol and VLB, followed by controlled shearing and extrusion. PEGylated Spherulites were prepared by incorporating 1,2-distearoyl-sn-glycero-3 phosphatidylethanolamine-N-[methoxy poly (ethylene glycol)] (DSPE-PEG 2000) in the lipid phase. Vesicles were characterized for size, entrapment efficiency and drug release. In vitro cell cytotoxicity and apoptosis study were performed on A549 cell line. Radiolabeling of VLB was performed by direct labeling with reduced technetium-99m. Binding affinity of Tc- labelled complexes was assessed by diethylenetriaminepenta acetic acid (DTPA) challenge test. Biodistribution study was done in Sprague Dawley rats. Dynamic light scattering and Transmission electron micrographs confirmed that PEGylated and non-PEGylated Spherulites were discrete, spherical and exhibited the size range of 120-130 nm. Non-PEGylated and PEGylated Spherulites had an entrapment efficiency of 95.65% and 94.2% respectively. In vitro drug release study indicated VLB plain drug solution diffused completely within 24 h, however, Non-PEGylated and PEGylated Spherulites showed similar release pattern till 48 h. Results of cell line study showed that cells treated with VLB loaded Spherulites showed more cytotoxicity and underwent high degree of apoptosis at lower concentration compared to the VLB solution. Radiolabeled complex was stable in saline and serum, further, DTPA challenge study ensured the high binding strength. Gamma Scintigraphy displayed that PEGylated Spherulites were localized within lungs at higher concentration than non-PEGylated followed by plain drug.
酒石酸长春瑞滨(VLB)是治疗非小细胞肺癌的一线化疗药物,但其非特异性分布会导致不必要的副作用。本研究的目的是制备用于靶向肺部的载药球晶。球晶由大豆卵磷脂(SPC)、胆固醇(Chol)、油酸钾和甘露醇组成。使用 SPC、Chol 和油酸钾制备的脂质体在包含甘露醇和 VLB 的水相分散体中,然后进行受控剪切和挤压。通过在脂质相中加入 1,2-二硬脂酰基-sn-甘油-3-磷酸乙醇胺-N-[甲氧基聚(乙二醇)](DSPE-PEG 2000)制备聚乙二醇化球晶。对载药球晶的粒径、包封率和药物释放进行了表征。在 A549 细胞系上进行了细胞毒性和细胞凋亡的体外研究。通过直接用还原态锝-99m 进行标记来进行 VLB 的放射性标记。通过二乙三胺五乙酸(DTPA)挑战试验评估 Tc 标记配合物的结合亲和力。在 Sprague Dawley 大鼠中进行了生物分布研究。动态光散射和透射电子显微镜证实,聚乙二醇化和非聚乙二醇化球晶是离散的、球形的,粒径范围为 120-130nm。非聚乙二醇化和聚乙二醇化球晶的包封效率分别为 95.65%和 94.2%。体外药物释放研究表明,VLB 普通药物溶液在 24h 内完全扩散,然而,非聚乙二醇化和聚乙二醇化球晶在 48h 内显示出相似的释放模式。细胞系研究结果表明,与 VLB 溶液相比,载药球晶处理的细胞在较低浓度下表现出更高的细胞毒性和更高程度的细胞凋亡。放射性标记的配合物在盐水中和血清中稳定,进一步的 DTPA 挑战研究确保了高结合强度。伽马闪烁成像显示,聚乙二醇化球晶在肺部的浓度高于非聚乙二醇化球晶,随后是普通药物。